8-K Announcements
6Material company update
May 15, 2026·SEC
Material company update
Mar 31, 2026·SEC
Material company update
Feb 27, 2026·SEC
Brainstorm Cell Therapeutics Inc.(BCLI)Earnings, Financials & Key Ratios
BCLI•NASDAQ
$1.30
Price updated Jul 6, 2026
AboutBrainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and Phase II clinical trial for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other neurodegenerative diseases. The company has a partnership with Catalent for manufacturing NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.Show more
- Revenue$0
- EBITDA-$10M+14.8%
- Net Income-$10M-188.7%
- EPS (Diluted)-1.11-150.7%
BCLI Price & Volume
Brainstorm Cell Therapeutics Inc. (BCLI) stock price & volume — 10-year historical chart
Loading chart...
Persistent Revenue Absence Signals Imminent Insolvency Risk
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent Insolvency and Dilution
Key Thesis Takeaways
- Brainstorm Cell Therapeutics remains in a precarious pre-commercial state, characterized by nine consecutive quarters of zero revenue and an accelerating erosion of its financial foundation.
- The company's reliance on equity-based compensation, which reached $717,000 in 2025Q1, highlights a structural dependence on dilution to fund ongoing R&D and SG&A expenses.
- Given the critical liquidity crisis evidenced by a cash balance of only $29,000 as of 2025Q4, the firm faces an existential threat that necessitates immediate capital intervention to maintain operations.
Verdict Logic
the company's cash reserves have dwindled to a critical $29,000, creating an immediate risk of insolvency that outweighs any potential upside from its therapeutic pipeline.
BCLI Growth Metrics
Brainstorm Cell Therapeutics Inc. (BCLI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM13.67%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM53.47%
Return on Capital
10 Years-146.75%
5 Years-148.74%
3 Years-
Last Year-
BCLI Recent Earnings
Brainstorm Cell Therapeutics Inc. (BCLI) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)
Q2 2026Latest
May 15, 2026Metric
Actual
Est
EPS
$0.19+32.1%
$0.28
Rev
—
—
Q2 2026
May 14, 2026Metric
Actual
Est
EPS
$0.22+21.4%
$0.28
Rev
—
—
Q2 2026
Mar 31, 2026Metric
Actual
Est
EPS
$0.20+44.4%
$0.36
Rev
—
—
Q4 2025
Nov 14, 2025Metric
Actual
Est
EPS
$0.91-160.0%
$0.35
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $0.19vs $0.28+32.1% | — |
| Q2 2026 | May 14, 2026 | $0.22vs $0.28+21.4% | — |
| Q2 2026 | Mar 31, 2026 | $0.20vs $0.36+44.4% | — |
| Q4 2025 | Nov 14, 2025 | $0.91vs $0.35-160.0% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Brainstorm Cell Therapeutics Inc. (BCLI)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.30 | $14.35M | -1.17 | — | — | — | — | |
| $3.29 | $330.34M | -4.84 | 75.76% | -98.83% | -80.73% | — | |
| $2.99 | $348.51M | -2.60 | -51.24% | -2056.79% | -58.89% | — | |
| $3.41 | $142M | -1002.94 | 10.37% | 52.16% | — | — | |
| $73.15 | $1.43B | -7.52 | -43.89% | -284.18% | -87% | — | |
| $0.38 | $3.97M | -0.18 | — | — | -246.04% | — |
Compare BCLI vs Peers
Brainstorm Cell Therapeutics Inc. (BCLI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BCLI SEC Filings & Documents
Brainstorm Cell Therapeutics Inc. (BCLI) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when BCLI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BCLI Frequently Asked Questions
Brainstorm Cell Therapeutics Inc. (BCLI) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is BCLI profitable?
Brainstorm Cell Therapeutics Inc. (BCLI) reported a net loss of $9.6M for fiscal year 2025.
Dividend & Returns
What is Brainstorm Cell Therapeutics Inc.'s free cash flow?
Brainstorm Cell Therapeutics Inc. (BCLI) had negative free cash flow of $6.7M in fiscal year 2025, likely due to heavy capital investments.